Cost of specialized addiction treatment of clients with fetal alcohol spectrum disorder in Canada

BMC Public Health

Jürgen Rehm³  Karen Urbanoski¹  Larry Burd²  Shannon Lange¹  Svetlana Popova⁴ 

[1] 2Dalla Lana School of Public Health, University of Toronto, 155 College St, Toronto, ON M5T 3M7, Canada;5Department of Pediatrics, University of North Dakota School of Medicine, 501 North Columbia Rd, Grand Forks, ND 58203, USA;6Epidemiological Research Unit, Klinische Psychologie and Psychotherapie, Technische Universität Dresden, Chemnitzer Str 46, Dresden D-01187, Germany;4Institute of Medicine, University of Toronto, 1 King's College Circle, Toronto, ON M5S 1A8, Canada

关键词: Canada;    Cost;    Utilization;    Specialized treatment;    Addiction;    Fetal alcohol spectrum disorder;    Fetal alcohol syndrome;   

Others  :  1162112
DOI  :  10.1186/1471-2458-13-570

 received in 2013-01-14, accepted in 2013-06-07,  发布年份 2013

【 摘 要 】

Background

Individuals with Fetal Alcohol Spectrum Disorder (FASD) constitute a special population that may be at particularly high risk for substance use. The purpose of the current study was to estimate the utilization of specialized addiction treatment services (SATS) and the associated cost, as a part of the total cost of health care associated with FASD in Canada.

Methods

The current study was a modeling study. Data on SATS by lifetime mental disorder status were obtained from the Drug and Alcohol Treatment Information System (DATIS) in Ontario, Canada for 2010/11. The number of clients with FASD who received SATS in Ontario in 2010/11 was estimated, assuming that approximately 37% (confidence interval: 21.6%-54.5%) of individuals with FASD abuse or are addicted to alcohol and/or drugs and that their utilization rate of SATS is the same as those for people with a lifetime mental disorder. The data from DATIS was then extrapolated to the total Canadian population.

Results

The cost of SATS for clients with FASD in Canada in 2010/11 ranged from $1.65 million Canadian dollars (CND) to $3.59 million CND, based on 5,526 outpatient visits and 9,529 resident days. When the sensitivity analysis was performed the cost of SATS ranged from $979 thousand CND to $5.34 million CND.

Conclusions

Special attention must be paid to at-risk groups of individuals such as those with FASD, in order to reduce the likelihood of the development of co-morbid substance abuse problems, and thus, reducing the overall burden on Canadian society.

【 授权许可】

   
2013 Popova et al.; licensee BioMed Central Ltd.

【 图 表 】

Figure 1.

Figure 2.

Figure 3.

Figure 4.

Figure 5.

【 参考文献 】

• [1]Popova S, Stade B, Lange S, Rehm J: A model for estimating the economic impact of fetal alcohol spectrum disorder. J Popul Ther Clin Pharmacol 2012, 19:e51-e65.
• [2]Popova S, Stade B, Lange S, Mihic A, Rehm J: Methodology for estimating the economic impact of fetal alcohol spectrum disorder. Canada: Public Health Agency of Canada; 2012. http://knowledgex.camh.net/reports/Documents/Popova_etalMethodologySummary_March30_12Final_E.pdf webcite
• [3]Burd L, Carlson C, Kerbeshian J: Fetal alcohol spectrum disorders and mental illness. Int J Disabil Hum Dev 2007, 6:383-396.
• [4]Popova S, Lange S, Mihic A, Bekmuradov D, Rehm J: Prevalence of fetal alcohol spectrum disorder in correctional systems: a systematic literature review. Can J Public Health 2011, 102:336-340.
• [5]Lange S, Rehm J, Bekmuradov D, Mihic A, Popova S: Risk of incarceration for individuals with prenatal alcohol exposure. Am J Epidemiol 2012, 176:80-82.
• [6]Streissguth AP, Barr HM, Kogan J, Bookstein FL: Understanding the occurrence of secondary disabilities in clients with fetal alcohol syndrome (FAS) and fetal alcohol effects (FAE). Seattle, Washington: University of Washington; 1996.
• [7]Famy C, Streissguth AP, Unis AS: Mental illness in adults with fetal alcohol syndrome or fetal alcohol effects. Am J Psychiatry 1998, 155:552-554.
• [8]Clark E, Lutke J, Minnes P, Ouellette-Kuntz H: Secondary disabilities among adults with fetal alcohol spectrum disorder in British Columbia. J FAS Int 2004, 2:e13.
• [9]Streissguth AP, Bookstein FL, Barr HM, Sampson PD, O’Malley K, Young JK: Risk factors for adverse life outcomes in fetal alcohol syndrome and fetal alcohol effects. J Dev Behav Pediatr 2004, 25:228-238.
• [10]Grant T, Huggins J, Connor P, Pedersen JY, Whitney N, Streissguth A: A pilot community intervention for young women with fetal alcohol spectrum disorders. Community Ment Health J 2004, 40:499-511.
• [11]Streissguth AP: FASD and Secondary Effects. Longitudinal study conducted by Dr. Anne Streissguth, Washington. Prepared by Diana Fox, for FASEout. Ottawa; 2008. http://www.faseout.ca/eng/training/downloads/2008/websitesecondarydisabilities2008.ppt webcite
• [12]Burd L, Klug MG, Martsolf JT, Kerbeshian J: Fetal alcohol syndrome: neuropsychiatric phenomics. Neurotoxicol Teratol 2003, 25:697-705.
• [13]Fryer SL, McGee CL, Matt GE, Riley EP, Mattson SN: Evaluation of psychopathological conditions in children with heavy prenatal alcohol exposure. Pediatrics 2007, 119:e733-e741.
• [14]Abel EL: Fetal alcohol abuse syndrome. New York: Plenum Press; 1998.
• [15]Rush B: Tiered frameworks for planning substance use service delivery systems: origins and key principles. Nord Stud Alcohol Drugs 2010, 27:617-636.
• [16]McGovern MP, Xie H, Segal SR, Siembab L, Drake RE: Addiction treatment services and co-occurring disorders: prevalence estimates, treatment practices, and barriers. J Subst Abuse Treat 2006, 31:267-275.
• [17]Bartels SJ, Drake RE, Wallach MA: Long-term course of substance use disorders among patients with severe mental illness. Psych Serv 1995, 46:248-251.
• [18]Carey M, Carey K, Meisler A: Psychiatric symptoms in mentally ill chemical abusers. J Nerv Ment Dis 1991, 179:136-138.
• [19]Enns MW, Swenson JR, McIntyre RS, McIntyre RS, Swinson RP, Kennedy SH, CANMAT Depression Work Group: Clinical guidelines for the treatment of depressive disorders: VII comorbidity. Can J Psychiat 2001, 46(Suppl 1):77S-90S.
• [20]Haywood TW, Kravitz HM, Grossman LS, Cavanaugh JL Jr, Davis JM, Lewis DA: Predicting the “revolving door” phenomenon among patients with schizophrenic, schizoaffective, and affective disorders. Am J Psychiat 1995, 152:856-861.
• [21]Moos RH, Mertens JR, Brennan PL: Rates and predictors of four-year readmission among late-middle-aged and older substance abuse patients. J Stud Alc 1994, 55:561-570.
• [22]Rouillon F: Epidemiology of panic disorder. Encephale 1996, 22(Spec Iss 5):25-34.
• [23]Ogborne AC, Braun K, Rush BR: Developing an integrated information system for specialized addiction treatment agencies. J Behav Health Serv Res 1998, 25:100-107.
• [24]Rotondi NK, Rush B: Monitoring utilization of a large scale addiction treatment system: The Drug and Alcohol Treatment Information System (DATIS). Sub Abuse Res Treat 2012, 6:73-84.
• [25]Public Health Agency of Canada (PHAC): Fetal alcohol spectrum disorder (FASD): A framework for action. Ottawa, ON: PHAC; 2003. http://www.phac-aspc.gc.ca/publicat/fasd-fw-etcaf-ca/pdf/fasd-fw_e.pdf webcite
• [26]Roberts G, Nanson J: Best practices. Fetal alcohol syndrome/fetal alcohol effects and the effects of other substance use during pregnancy. Ottawa, ON: Canada’s Drug Strategy Division, Health Canada; 2000.
• [27]Statistics Canada: Table 051–0001 - Estimates of population, by age group and sex for July 1, Canada, provinces and territories, annual (persons unless otherwise noted). 2012. Statistics Canada, CANSIM (database): http://www.statcan.gc.ca/tables-tableaux/sum-som/l01/cst01/demo02a-eng.htm webcite
• [28]Lipsey M, Wilson DB: Practical meta-analysis. Applied social research methods series (Vol. 49). California: Sage Publications; 2001.
• [29]Cochran WG: The combination of estimates from different experiments. Biometrics 1954, 8:101-129.
• [30]Higgins JP, Thompson SG: Quantifying heterogeneity in a meta-analysis. Stat Med 2002, 21:1539-1558.
• [31]Mantel N, Haenszel W: Statistical aspects of the analysis of data from retrospective studies of disease. J Natl Cancer Inst 1959, 22(4):719-748.
• [32]Begg CB, Mazumdar M: Operating characteristics of a rank correlation test for publication bias. Biometrics 1994, 50:1088-1101.
• [33]Egger M, Smith GD, Schneider M, Minder C: Bias in meta-analysis detected by a simple, graphical test. BMJ 1997, 315:629-634.
• [34]Duval SJ, Tweedie RL: Trim and fill: a simple funnel plot based method of testing and adjusting for publication bias in meta-analysis. Biometrics 2000, 56:276-284.
• [35]Pei J, Denys K, Hughes J, Rasmussen C: Mental health issues in fetal alcohol spectrum disorder. J Ment Health 2011, 20:438-448.
• [36]Streissguth AP, Barr HM, Bookstein FL, Sampson PD, Olson HC: The long-term neurocognitive consequences of prenatal alcohol exposure: a 14-year study. Psychol Sci 1999, 10:186-190.
• [37]Ministry of Health and Long-Term Care (MOHLTC): Mental health and addictions in Ontario LHINs. Health System Intelligence Project. Toronto, ON: Health System Intelligence Project, MOHLTC; 2008.
• [38]Health Canada: A report on mental illnesses in Canada. Ottawa, Canada; 2002.
• [39]Popova S, Lange S, Burd L, Chudley AE, Clarren SK, Rehm J: Cost of fetal alcohol spectrum disorder diagnosis in Canada. PLoS One 2013, 8:e60434.
• [40]Popova S, Lange S, Burd L, Rehm J: Health care burden and cost associated with fetal alcohol syndrome in Canada: based on official Canadian data. PLoS One 2012, 7:e43024.
• [41]Castel S, Rush B, Urbanoski K, Toneatto T: Overlap of clusters of psychiatric symptoms among clients of a comprehensive addiction treatment service. Psychol Addict Behav 2006, 20:28-35.
• [42]Grant BF, Stinson FS, Dawson DA, Chou SP, Dufour MC, Compton W, Pickering RP, Kaplan K: Prevalence and co-occurrence of substance use disorders and independent mood and anxiety disorders: results from the national epidemiological survey on alcohol and related conditions. Arch Gen Psychiat 2004, 61:807-816.
• [43]Rush B, Urbanoski KI, Bassani D, Castel S, Wild TC, Strike C, Kimberley D, Somers J: Prevalence of co-occurring substance use and other mental disorders in the Canadian population. Can J Psychiat 2008, 53:800-809.
• [44]Elliott E, Payne JM, Morris A, Haan E, Bower C: Fetal alcohol syndrome: a prospective national surveillance study. Arch Dis Child 2008, 93:732-737.
• [45]O'Connor MJ, Shah B, Whaley S, Cronin P, Gunderson B, Graham J: Psychiatric illness in a clinical sample of children with prenatal alcohol exposure. Am J Drug Alcohol Abuse 2002, 28:743-754.
• [46]Paintner A, Williams AD, Burd L: Fetal alcohol spectrum disorders—Implications for child neurology, Part 1: Prenatal exposure and dosmetry. J Child Neurol 2012, 27:258-263.
• [47]Paintner A, Williams AD, Burd L: Fetal alcohol spectrum disorders—Implications for child neurology, Part 2: Diagnosis and management. J Child Neurol 2012, 27:355-362.
• [48]Burd L, Fast D, Conry J, Williams A: Fetal alcohol spectrum disorders as a marker for increased risk of involvement with corrections systems. J Psych Law 2011, 28:559-583.
• [49]Burd L, Selfridge RH, Klug MG, Juelson T: Fetal alcohol syndrome in the Canadian corrections system. J FAS Int 2003, 1:1-10.
• [50]Gelb K, Rutman D: Substance using women with FASD and FASD prevention: A literature review on promising approaches in substance use treatment and care for women with FASD. Victoria, BC: University of Victoria; 2011. http://www.uvic.ca/hsd/socialwork/assets/docs/research/Substance%20Using%20Women%20with%20FASD-LitReview-web.pdf webcite